Efficacy evaluation of imatinib in the treatment of patients with gastrointestinal stromal tumors.

@article{Zong2011EfficacyEO,
  title={Efficacy evaluation of imatinib in the treatment of patients with gastrointestinal stromal tumors.},
  author={Liang Zong and Ping Chen and Wei Zhao and Lei Shi},
  journal={The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology},
  year={2011},
  volume={22 5},
  pages={479-85}
}
BACKGROUND/AIMS Published data on the dose of imatinib to treat gastrointestinal stromal tumors seemed inconclusive. To derive a more precise estimation of dose of imatinib to treat gastrointestinal stromal tumors, a meta-analysis was performed. MATERIAL AND METHODS Studies have been identified by searching PubMed and Embase. Inclusion criteria were patients with incurable or advanced gastrointestinal stromal tumors, received chemotherapy of imatinib of 400 mg once a day (low-dose group) or… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
1 Extracted Citations
22 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 22 references

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

  • GD Demetri, M von Mehren, CD Blanke
  • N Engl J Med
  • 2002
Highly Influential
4 Excerpts

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT

  • CD Blanke, GD Demetri, M Von Mehren
  • J Clin Oncol
  • 2008
1 Excerpt

Evaluation of imatinib mesylate in patients with large volume gastrointestinal stromal tumors

  • DM Byrd, GD Demetri, H Joensuu
  • J Clin Oncol
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…